Atsuko Ikenouchi

Dr. Atsuko Ikenouchi

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
Reiji YoshimuraReiji Yoshimura
Reiji Yoshimura
AIAtsuko Ikenouchi
Atsuko Ikenouchi
HHHikaru Hori
Hikaru Hori
WUWakako Umene-Nakano
Wakako Umene-Nakano
AKAsuka Katsuki
Asuka Katsuki
JNJun Nakamura
Jun Nakamura

17 October 2013 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KSKazunari Sugita
Kazunari Sugita
AIAtsuko Ikenouchi
Atsuko Ikenouchi
YNYasuko Nakayama
Yasuko Nakayama
HYHaruna Yoshioka
Haruna Yoshioka
TNTakashi Nomura
Takashi Nomura
KKKenji Kabashima
Kenji Kabashima
Pellagra is a photosensitivity syndrome characterized by three “D's”: diarrhea, dermatitis, and dementia as a result of niacin deficiency. However, the molecular mechanisms of photosensitivity dermatitis, the hallmark abnormality of this syndrome, remain unclear. We prepared niacin deficient mice in order to develop a murine model of pellagra. Niacin deficiency induced photosensitivity and severe diarrhea with weight loss. In addition, niacin deficient mice exhibited elevated expressions of COX-2 and PGE syntheses (Ptges) mRNA. Consistently, photosensitivity was alleviated by a COX inhibitor, deficiency of Ptges, or blockade of EP4 receptor signaling. Moreover, enhanced PGE2 production in niacin deficiency was mediated via ROS production in keratinocytes. In line with the above murine findings, human skin lesions of pellagra patients confirmed the enhanced expression of Ptges. Niacin deficiency-induced photosensitivity was mediated through EP4 signaling in response to increased PGE2 production via induction of ROS formation.

1 October 2008 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
AIAtsuko Ikenouchi
Atsuko Ikenouchi
RYReiji Yoshimura
Reiji Yoshimura
NUNobuhisa Ueda
Nobuhisa Ueda
YKYuki Kodama
Yuki Kodama
WUWakako Umene-Nakano
Wakako Umene-Nakano
JNJun Nakamura
Jun Nakamura
Continuous decrease in serum brain-derived neurotrophic factor (BDNF) levels in a neuropsychiatric syndrome of systemic lupus erythematosus patient with organic brain changes Atsuko Ikenouchi-Sugita, Reiji Yoshimura, Nobuhisa Ueda, Yuki Kodama, Wakako Umene-Nakano, Jun NakamuraDepartment of Psychiatry, School of Medicine, University of Occupational and Environmental Health, Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan In the present study, the authors reported on a case in neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE) with irreversible organic brain changes. The authors also longitudinally investigated serum brain-derived neurotrophic factor (BDNF) levels in the patient. We found that serum BDNF levels in the NPSLE patient with irreversible organic brain change were consistently low, independent of the severity of psychiatric symptoms. Thus, the longitudinal measurement of serum BDNF levels might be useful in predicting the prognosis of NPSLE.Keywords: brain-derived neurotrophic factor; neuropsychiatric syndrome of systemic lupus erythematosus; organic brain change

16 December 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LNLeHoa Nguyen
LeHoa Nguyen
SKShingo Kakeda
Shingo Kakeda
KWKeita Watanabe
Keita Watanabe
AKAsuka Katsuki
Asuka Katsuki
KSKoichiro Sugimoto
Koichiro Sugimoto
Reiji YoshimuraReiji Yoshimura
Reiji Yoshimura
Higher cortisol levels due to a hyperactive hypothalamic–pituitary–adrenal axis have been reported in patients with major depressive disorder (MDD). Increased cortisol levels change both the brain morphology and function in MDD patients. The multivariate source-based morphometry (SBM) technique has been applied to investigate neuroanatomical changes in some neuropsychiatric diseases, but not MDD. We aimed to examine the alterations in gray matter (GM) networks and their relationship with serum cortisol levels in first-episode, drug-naïve MDD patients using SBM. Forty-two patients with MDD and 39 controls were recruited via interviews. Morning serum cortisol levels were measured, and high-resolution T1-weighted imaging followed by SBM analysis was performed in all participants. The patients had significantly higher serum cortisol levels than the controls. We found two GM sources, which were significantly different between patients with MDD and controls (prefrontal network, p < .01; insula-temporal network, p < .01). Serum cortisol levels showed a statistically significant negative correlation with the loading coefficients of the prefrontal network (r = − 0.354, p = 0.02). In conclusion, increased serum cortisol levels were associated with reductions in the prefrontal network in the early stage of MDD, and SBM may be a useful approach for analyzing structural MRI data.

29 January 2010 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
AIAtsuko Ikenouchi
Atsuko Ikenouchi
Reiji YoshimuraReiji Yoshimura
Reiji Yoshimura
TOTatsuya Okamoto
Tatsuya Okamoto
WUWakako Umene-Nakano
Wakako Umene-Nakano
NUNobuhisa Ueda
Nobuhisa Ueda
JNJun Nakamura
Jun Nakamura
Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious but potentially treatable disease. However, biological markers such as IgG index or IL-6 do not always reflect the severity of the psychotic symptoms of NPSLE. We hypothesized that serum BDNF levels may be a biological marker for reflecting the severity of the psychiatric symptoms of NPSLE. The participants enrolled in this study were 28 healthy volunteers and 54 Japanese SLE inpatients at the University Hospital of Occupational and Environmental Health, all of whom fulfilled the criteria for the classification of SLE. SLE patients were divided into the three groups: NPSLE with psychiatric symptoms including an acute confusional state, anxiety disorder, cognitive dysfunction, mood disorder, and psychosis (NP group); NPSLE without psychiatric symptoms (NN group); and SLE without neuropsychiatric symptoms (S group). The serum BDNF levels were measured by ELISA. Serum BDNF levels were significantly increased in the NP group (mean +/- SE = 37.0 +/- 5.46 ng/ml) compared with those in the other three groups (NN group; mean +/- SE = 9.1 +/- 2.44 ng/ml, P < 0.0001, S group; mean +/- SE = 10.4 +/- 2.51 ng/ml, P < 0.0001, healthy control; mean +/- SE = 11.44 +/- 0.69, P < 0.0001). Subsequently, serum BDNF levels were decreased in parallel with the improvement of psychiatric symptoms in the NP group. These results suggest that serum BDNF is a biological marker for the severity of psychiatric symptoms in NPSLE patients.

27 October 2011 in Human Psychopharmacology: Clinical and Experimental
Verified
Journal Article
Closed access
PDF file
AIAtsuko Ikenouchi
Atsuko Ikenouchi
RYReiji Yoshimura
Reiji Yoshimura
TKTaro Kishi
Taro Kishi
WUWakako Umene‐Nakano
Wakako Umene‐Nakano
HHHikaru Hori
Hikaru Hori
JNJun Nakamura
Jun Nakamura